MUMBAI (Thomson Financial) - Moody's Investors Service assigned a 'Ba3'
corporate family rating to APP Pharmaceuticals LLC, a unit of APP
Pharmaceuticals Inc -- which in turn will be a newly formed entity resulting
from the separation of Abraxis BioScience Inc into two independent publicly
traded companies.
The outlook for the rating is stable.
Moody's said the ratings are constrained by the increase in financial
leverage and deterioration of credit metrics resulting from incremental debt. In
addition, Moody's believes there is event risk associated with the complex and
highly regulated manufacturing and supply processes in the injectable
pharmaceutical industry.
In the past the company has experienced events of this nature including a
voluntary plant shut-down in 2005 in order to upgrade and re-validate a
manufacturing facility and constraints on the availability of certain products.
The ratings are also constrained by the limited scale of the company.
However, the ratings are supported by Moody's expectation for improvement in
credit metrics over the next twelve to eighteen months resulting from debt
repayment, the launch of new products from a strong pipeline, and favourable
industry fundamentals.
In addition, APP benefits from very high barriers to entry in the
injectable, generic pharmaceutical industry and has demonstrated a track record
of competing successfully with larger pharmaceutical companies.
Moody's also believes that infrastructure investments in recent years should
support increased manufacturing capacity and could reduce the likelihood of a
manufacturing or supply event.
"All ratings are subject to review of final documentation," the agency
concluded.
TFN.newsdesk@thomson.com
jro
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|